1. Market Research
  2. > Healthcare Market Trends
  3. > CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Singapore

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Singapore

Summary

GlobalData, the industry analysis specialist, has released its latest report, “CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Singapore”. The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in Singapore. It identifies the key trends in the country’s healthcare market and provides insights into its demographic, regulatory, and reimbursement landscape and healthcare infrastructure. Most importantly, the report provides valuable insights into the trends and segmentation of its pharmaceutical and medical device markets. It is built using data and information sourced from proprietary databases, secondary research, and in-house analysis by GlobalData’s team of industry experts.

Singapore’s population grew from 4.8 million in 2008 to 5.4 million in 2013, mainly due to the increase in the life expectancy (DoS, 2014). The value of the pharmaceuticals market increased from $489m in 2008 to $761m in 2013 at a Compound Annual Growth Rate (CAGR) of 9.3%, and this value is expected to increase further from $776m in 2014 to $873m in 2020 at a CAGR of 2.0% (Tarn et al., 2008; DoS, 2014; EDB, 2014c). In 2011, the output of the medical technology sector was SGD4.3 billion ($3.4 billion), which is expected to increase to SGD5 billion ($4 billion) in 2015 (EDB, 2014a).

These positive growth trends can primarily be attributed to -
- Government initiatives
- Universal healthcare coverage

Scope

The report provides information on the healthcare, regulatory, and reimbursement landscape in Singapore, and includes -
- Overview of the pharmaceutical market including size, segmentation, and key drivers and barriers
- Profiles and SWOT analyses of the major players in the pharmaceutical market: Haw Par Corporation, SciGen, Pfizer, Novartis and GlaxoSmithKline
- Insightful review of the reimbursement and regulatory landscape, with analysis covering details of the country’s healthcare reimbursement process, regulatory agencies and the approval processes for new drugs and medical devices
- Detailed analysis of the political and economic environment, covering economic indicators, demographics, healthcare infrastructure and healthcare expenditure
- An overview of the opportunities for and challenges to growth in the Singaporean healthcare market

Reasons to buy

This report will enhance your decision-making capability by allowing you to -
- Develop business strategies by understanding the trends shaping and driving Singapore’s healthcare market
- Drive revenues by understanding the key trends, reimbursement and regulatory policies, pharmaceutical market segments, and companies likely to affect Singapore’s healthcare market in the future
- Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors
- Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investment, and strategic partnership
- Identify, understand, and capitalize on the opportunities and challenges in Singapore’s healthcare market

Table Of Contents

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Singapore
1 Table of Contents
2 Introduction 18
2.1 GlobalData Report Guidance 18
3 Overview of Pharmaceutical and Medical Device Market 19
3.1 Pharmaceutical Market 19
3.1.1 Market Overview 19
3.1.2 Pharmaceutical Exports and Imports 24
3.1.3 Supply Channels 25
3.1.4 Market Segments 26
3.1.5 Overview of Major Disease Areas 29
3.1.6 Major Players 31
3.2 Medical Device Market 64
3.2.1 Market Overview 64
3.3 Market Drivers and Barriers 65
3.3.1 Drivers 65
3.3.2 Barriers 66
4 Market Access 68
4.1 Reimbursement and Payer Landscape 68
4.1.1 Overview of Healthcare System 68
4.1.2 Reimbursement Process 71
4.1.3 Overview of Insurance Providers 72
4.1.4 Patient Share in Healthcare Spending 76
4.1.5 Price Trends in the Healthcare Sector 78
4.1.6 Pricing Policies 79
4.2 Regulatory Landscape 79
4.2.1 Overview of Regulatory Agencies 79
4.2.2 Market Authorization Procedure for Pharmaceutical Products 84
4.2.3 New Medical Device Approval Process 89
4.2.4 Licensing Process for Pharmaceutical and Medical Device Manufacturing 92
4.2.5 Exports and Imports 94
4.2.6 Intellectual Property Rights 96
4.2.7 Clinical Trial Regulations 112
4.2.8 Pharmaceutical Advertising Regulations 118
4.2.9 Pharmacy Regulations 119
4.2.10 Labeling and Packaging Regulations 121
5 Country Analysis 125
5.1 Political Environment 125
5.1.1 Political Structure 125
5.1.2 Analysis of Current Political Environment 126
5.1.3 Healthcare Policy Initiatives 127
5.2 Economic Landscape 129
5.3 Economic Indicators 134
5.3.1 Gross Domestic Product 134
5.3.2 Gross National Income 140
5.3.3 Inflation 141
5.3.4 Currency Exchange Rate 145
5.3.5 Foreign Direct Investment 146
5.3.6 Foreign Exchange Reserves 147
5.3.7 Trade Balance 148
5.3.8 Government Structural Balance 150
5.3.9 Government Gross Debt 152
5.3.10 Major Industries 153
5.4 Demographics 154
5.4.1 Population 154
5.4.2 Education and Literacy 172
5.4.3 Employment 174
5.4.4 Disease Burden 175
5.5 Healthcare Infrastructure 178
5.5.1 Healthcare Facilities 178
5.5.2 Healthcare Parameters 182
5.5.3 Environmental Health 185
5.5.4 Healthcare Personnel 193
5.6 Healthcare Expenditure 198
5.6.1 Overview 198
5.6.2 Share of Public and Private Sectors 200
5.6.3 Major Components of Healthcare Spending 201
5.6.4 Spending in Pharmaceutical Research and Development 203
5.7 Trade Associations 205
5.7.1 The Singapore Association of Pharmaceutical Industries 205
5.7.2 The Singapore Medical Association 205
5.7.3 The Society for Emergency Medicine in Singapore 206
5.7.4 The Pharmaceutical Society of Singapore 206
5.7.5 The Healthcare Quality Society of Singapore 207
5.8 Trade Fairs 208
6 Opportunities and Challenges 209
6.1 Opportunities 209
6.2 Challenges 210
7 Appendix 212
7.1 Abbreviations 212
7.2 Bibliography 217
7.3 Research Methodology 235
7.3.1 Coverage 235
7.3.2 Secondary Research 236
7.3.3 Forecasts 236
7.3.4 Expert Panel 236
7.4 Disclaimer 237

1.1 List of Tables

Table 1: Pharmaceutical Market, Singapore, Revenue ($m), 2008-2013 23
Table 2: Pharmaceutical Market, Singapore, Revenue Forecast ($m), 2014-2020 23
Table 3: Pharmaceutical Market, Singapore, Exports and Imports ($bn), 2008-2013 25
Table 4: Pharmaceutical Market, Haw Par, Global, Major Products, 2014 32
Table 5: Pharmaceutical Market, SciGen, Global, Major Products, 2014 35
Table 6: Pharmaceutical Market, Pfizer, Global, Major Products, Revenue ($bn) and Annual Growth (%), 2013 38
Table 7: Pharmaceutical Market, Pfizer, Global, Late-Stage Pipeline, 2014 39
Table 8: Pharmaceutical Market, Novartis, Global, Major Products, Revenue ($bn) and Annual Growth (%), 2013 46
Table 9: Pharmaceutical Market, Novartis, Global, Planned Filings, 2014-2018 47
Table 10: Pharmaceutical Market, GlaxoSmithKline, Global, Major Products, Revenue ($bn) and Annual Growth (%), 2013 57
Table 11: Pharmaceutical Market, GlaxoSmithKline, Global, Late-Stage Pipeline, 2014 57
Table 12: Market Access, Singapore, Medisave Wage Contribution (%), 2014 73
Table 13: Market Access, Singapore, MediShield Premium Payment Scheme by Age Group ($), 2014 74
Table 14: Market Access, Singapore, Medisave-Approved Integrated Shield Plans Withdrawal Limit by Age Group ($), 2014 75
Table 15: Market Access, Singapore, Healthcare Spending, Out-of-Pocket Expenditure (%), 2008-2013 77
Table 16: Market Access, Singapore, Price of Pharmaceutical Products, Change in Average Price of Medicines (%), 2008-2013 78
Table 17: Market Access, Singapore, Registration Dossier Format, 2014 86
Table 18: Market Access, Singapore, Registration Dossier Format, 2014 87
Table 19: Market Access, Singapore, Registration Dossier Format, 2014 90
Table 20: Market Access, Singapore, GMP Certificate Fees for Medicinal Products and APIs ($), 2014 93
Table 21: Market Access, Singapore, Manufacturer's License Fees for Medicinal Products ($), 2014 94
Table 22: Market Access, Singapore, Manufacturer's License Fees for Medicinal Products ($), 2014 95
Table 23: Market Access, Singapore, Wholesale Dealer's License Fees for Medicinal Products ($), 2014 96
Table 24: Market Access, Singapore, Patent Co-operation Treaty (PCT), International Application Process, 2014 105
Table 25: Market Access, Singapore, Patent Filing Fees and Charges SGD ($), 2014 106
Table 26: Market Access, Singapore, Clinical Trial Certificates Issued, 2008-2013 115
Table 27: Market Access, Singapore, Clinical Trials by Therapeutic Area (%), 2013 116
Table 28: Market Access, Singapore, Target Processing Timelines of Clinical Trial, 2014 117
Table 29: Market Access, Singapore, Fees for Advertisement Permit ($), 2010 119
Table 30: Market Access, Singapore, Fees for Advertisement Permit ($), 2014 121
Table 31: Market Access, Singapore, Labeling Requirements, 2014 123
Table 32: Economic Indicators, Singapore, Gross Domestic Product per Capita ($), 2008-2013 135
Table 33: Economic Indicators, Singapore, Gross Domestic Product per Capita ($), Forecast, 2014-2020 136
Table 34: Economic Indicators, Singapore, Gross Domestic Product Annual Growth (%), 2008-2013 138
Table 35: Economic Indicators, Singapore, Gross Domestic Product Annual Growth (%), Forecast, 2014-2020 139
Table 36: Economic Indicators, Singapore, Gross National Income per Capita ($), 2008-2013 140
Table 37: Economic Indicators, Singapore, Consumer Price Index, 2008-2013 142
Table 38: Economic Indicators, Singapore, Average Consumer Price Index, Forecast, 2014-2020 142
Table 39: Economic Indicators, Singapore, Average Consumer Price Index, Annual Change (%), 2008-2013 143
Table 40: Economic Indicators, Singapore, Average Consumer Price Index, Annual Change (%), Forecast, 2014-2020 144
Table 41: Economic Indicators, Singapore, Currency Exchange Rate (SGD/$), 2008-2013 145
Table 42: Economic Indicators, Singapore, Foreign Direct Investment ($bn), 2008-2013 146
Table 43: Economic Indicators, Singapore, Foreign Exchange Reserves ($bn), 2008-2013 147
Table 44: Economic Indicators, Singapore, Imports of Goods and Services ($bn), 2008-2013 149
Table 45: Economic Indicators, Singapore, Exports of Goods and Services ($bn), 2008-2013 150
Table 46: Economic Indicators, Singapore, General Government Structural Balance ($bn), 2008-2013 151
Table 47: Economic Indicators, Singapore, General Government Gross Debt ($bn), 2008-2013 152
Table 48: Economic Indicators, Singapore, Major Industries, Industrial Sector, Gross Value Added ($bn), 2012-2013 154
Table 49: Demographics, Singapore, Population (million), 2008-2013 155
Table 50: Demographics, Singapore, Population Forecast (million), 2014-2020 156
Table 51: Demographics, Singapore, Population Distribution by Age Group (%), 2008-2013 158
Table 52: Demographics, Singapore, Population Distribution by Age Group Forecast (%), 2014-2020 159
Table 53: Demographics, Singapore, Births (per 1,000 Population), 2008-2013 160
Table 54: Demographics, Singapore, Mortality (per 1,000 Population), 2008-2013 161
Table 55: Demographics, Singapore, Major Causes of Mortality (‘000), 2008 163
Table 56: Demographics, Singapore, Children Under Five Mortality Rate (per 1,000 Live Births), 2008-2013 164
Table 57: Demographics, Singapore, Immunization Rate (%), 2008-2013 165
Table 58: Demographics, Singapore, Major Causes of Male Mortality (per 1,000 Population), 2008 167
Table 59: Demographics, Singapore, Major Causes of Female Mortality (per 1,000 Population), 2008 168
Table 60: Demographics, Singapore, Gender Ratio (M/F), 2008-2013 169
Table 61: Demographics, Singapore, Life Expectancy at Birth (Years), 2008-2013 171
Table 62: Demographics, Singapore, Student Enrollment by Level of Education (%), 2013 173
Table 63: Demographics, Singapore, Unemployment Rate (%), 2008-2013 175
Table 64: Demographics, Singapore, Major Causes of Patient Discharge (%), 2012 176
Table 65: Demographics, Singapore, Major Diseases, DALYs (per 100,000 Population), 2004 177
Table 66: Healthcare Infrastructure, Singapore, Hospitals, 2008-2013 180
Table 67: Healthcare Infrastructure, Singapore, Public and Private Hospitals, 2008-2013 181
Table 68: Healthcare Infrastructure, Singapore, Hospitals Beds (per 1,000 Population), 2008-2013 182
Table 69: Healthcare Infrastructure, Singapore, Beds by Type of Hospital, 2008-2013 183
Table 70: Healthcare Infrastructure, Singapore, Number of Physicians (per 10,000 Population), 2008-2013 184
Table 71: Healthcare Infrastructure, Singapore, PM10 (µg/m³), 2008-2013 186
Table 72: Healthcare Infrastructure, Singapore, CO2 Emissions (Million Metric Tons), 2008-2013 188
Table 73: Healthcare Infrastructure, Singapore, Water Pollutants (Million Metric Tons), 2008-2013 189
Table 74: Healthcare Infrastructure, Singapore, Waste Generated (million Tons), 2008-2013 190
Table 75: Healthcare Infrastructure, Singapore, Waste Handling Methods Share (%), 2013 191
Table 76: Healthcare Infrastructure, Singapore, Waste Recycling Share by Type of Waste (%), 2013 193
Table 77: Healthcare Infrastructure, Singapore, Nurses (per 1,000 Population), 2008-2013 194
Table 78: Healthcare Infrastructure, Singapore, Midwives (per 1,000 Population), 2008-2013 195
Table 79: Healthcare Infrastructure, Singapore, Dentists (per 1,000 Population), 2008-2013 196
Table 80: Healthcare Infrastructure, Singapore, Pharmacists (per 1,000 Population), 2008-2013 197
Table 81: Healthcare Infrastructure, Singapore, Healthcare Expenditure (% of GDP), 2008-2013 199
Table 82: Healthcare Infrastructure, Singapore, Public-Private Share (%), 2008-2013 201
Table 83: Healthcare Infrastructure, Singapore, Share of Expenditure of Major Components of Healthcare Spending (%), 2014 202
Table 84: Healthcare Infrastructure, Singapore, RandD Expenditure ($m), 2008-2013 204
Table 85: Trade Fairs, Singapore, Major Healthcare Trade Fairs, 2014 208

1.1 List of Figures

Figure 1: Pharmaceutical Market, Singapore, Revenue ($m), 2008-2013 22
Figure 2: Pharmaceutical Market, Singapore, Revenue Forecast ($m), 2014-2020 23
Figure 3: Pharmaceutical Market, Singapore, Exports and Imports ($bn), 2008-2013 24
Figure 4: Pharmaceutical Market, Singapore, Distribution Channels, 2014 26
Figure 5: Healthcare Market, Singapore, Drivers and Barriers, 2014 67
Figure 6: Market Access, Singapore, Healthcare Insurance System, 2014 70
Figure 7: Market Access, Singapore, Healthcare Financing System, 2014 71
Figure 8: Market Access, Singapore, Healthcare Spending, Out-of-Pocket Expenditure (%), 2008-2013 77
Figure 9: Market Access, Singapore, Price of Pharmaceutical Products, Change in Average Price of Medicines (%), 2008-2013 78
Figure 10: Market Access, Singapore, Structure of the Ministry of Health, 2014 80
Figure 11: Market Access, Singapore, Structure of the Health Sciences Authority, 2014 83
Figure 12: Market Access, Singapore, New Drug Application Types, 2014 85
Figure 13: Market Access, Singapore, New Drug Approval Process, 2014 89
Figure 14: Market Access, Singapore, Licensing Process for Manufacturing, 2014 93
Figure 15: Market Access, Singapore, Licensing Process for Import/Export, 2014 96
Figure 16: Market Access, Singapore, National Patent Approval Process, 2014 101
Figure 17: Market Access, Singapore, PCT National Phase Entry Process, 2014 103
Figure 18: Market Access, Singapore, International Patent Approval Process, 2014 104
Figure 19: Market Access, Singapore, National Trademark Approval Process, 2014 111
Figure 20: Market Access, Singapore, International Trademark Approval Process, 2014 112
Figure 21: Market Access, Singapore, Clinical Trial Certificates Issued, 2008-2013 115
Figure 22: Market Access, Singapore, Clinical Trials by Therapeutic Area (%), 2013 116
Figure 23: Market Access, Singapore, Clinical Trial Approval Process, 2014 117
Figure 24: Market Access, Singapore, Pharmacy Regulations, 2014 121
Figure 25: Economic Indicators, Singapore, Gross Domestic Product per Capita ($), 2008-2013 135
Figure 26: Economic Indicators, Singapore, Gross Domestic Product per Capita ($), Forecast, 2014-2020 136
Figure 27: Economic Indicators, Singapore, Gross Domestic Product Annual Growth (%), 2008-2013 138
Figure 28: Economic Indicators, Singapore, Gross Domestic Product Annual Growth (%), Forecast, 2014-2020 139
Figure 29: Economic Indicators, Singapore, Gross National Income per Capita ($), 2008-2013 140
Figure 30: Economic Indicators, Singapore, Consumer Price Index, 2008-2013 141
Figure 31: Economic Indicators, Singapore, Average Consumer Price Index, Forecast, 2014-2020 142
Figure 32: Economic Indicators, Singapore, Average Consumer Price Index, Annual Change (%), 2008-2013 143
Figure 33: Economic Indicators, Singapore, Average Consumer Price Index, Annual Change (%), Forecast, 2014-2020 144
Figure 34: Economic Indicators, Singapore, Currency Exchange Rate (SGD/$), 2008-2013 145
Figure 35: Economic Indicators, Singapore, Foreign Direct Investment ($bn), 2008-2013 146
Figure 36: Economic Indicators, Singapore, Foreign Exchange Reserves ($bn), 2008-2013 147
Figure 37: Economic Indicators, Singapore, Imports of Goods and Services ($bn), 2008-2013 148
Figure 38: Economic Indicators, Singapore, Exports of Goods and Services ($bn), 2008-2013 150
Figure 39: Economic Indicators, Singapore, Government Structural Balance ($bn), 2008-2013 151
Figure 40: Economic Indicators, Singapore, General Government Gross Debt ($bn), 2008-2013 152
Figure 41: Economic Indicators, Singapore, Major Industries, Industrial Sector, Gross Value Added ($bn), 2012-2013 153
Figure 42: Demographics, Singapore, Population (million), 2008-2013 155
Figure 43: Demographics, Singapore, Population Forecast (million), 2014-2020 156
Figure 44: Demographics, Singapore, Population Distribution by Age Group (%), 2008-2013 158
Figure 45: Demographics, Singapore, Population Distribution by Age Group Forecast (%), 2014-2020 159
Figure 46: Demographics, Singapore, Births (per 1,000 Population), 2008-2013 160
Figure 47: Demographics, Singapore, Mortality (per 1,000 Population), 2008-2013 161
Figure 48: Demographics, Singapore, Major Causes of Mortality (‘000), 2008 162
Figure 49: Demographics, Singapore, Children Under Five, Mortality Rate (per 1,000 Live Births), 2008-2013 164
Figure 50: Demographics, Singapore, Immunization Rate (%), 2008-2013 165
Figure 51: Demographics, Singapore, Major Causes of Male Mortality (per 1,000 Population), 2008 166
Figure 52: Demographics, Singapore, Major Causes of Female Mortality (per 1,000 Population), 2008 167
Figure 53: Demographics, Singapore, Gender Ratio (M/F), 2008-2013 169
Figure 54: Demographics, Singapore, Life Expectancy at Birth (Years), 2008-2013 171
Figure 55: Demographics, Singapore, Student Enrollment by Level of Education (%), 2013 173
Figure 56: Demographics, Singapore, Unemployment Rate (%), 2008-2013 174
Figure 57: Demographics, Singapore, Major Causes of Patient Discharge (%), 2012 175
Figure 58: Demographics, Singapore, Major Diseases, DALYs (per 100,000 Population), 2004 177
Figure 59: Healthcare Infrastructure, Singapore, Hospitals, 2008-2013 180
Figure 60: Healthcare Infrastructure, Singapore, Public and Private Hospitals, 2008-2013 181
Figure 61: Healthcare Infrastructure, Singapore, Hospitals Beds (per 1,000 Population), 2008-2013 182
Figure 62: Healthcare Infrastructure, Singapore, Beds by Type of Hospital, 2008-2013 183
Figure 63: Healthcare Infrastructure, Singapore, Number of Physicians (per 10,000 Population), 2008-2013 184
Figure 64: Healthcare Infrastructure, Singapore, PM10 (µg/m³), 2008-2013 186
Figure 65: Healthcare Infrastructure, Singapore, CO2 Emissions (Million Metric Tons), 2008-2013 188
Figure 66: Healthcare Infrastructure, Singapore, Water Pollutants (Million Metric Tons), 2008-2013 189
Figure 67: Healthcare Infrastructure, Singapore, Waste Generated (million Tons), 2008-2013 190
Figure 68: Healthcare Infrastructure, Singapore, Waste Handling Methods Share (%), 2013 191
Figure 69: Healthcare Infrastructure, Singapore, Waste Recycling Share by Type of Waste (%), 2013 192
Figure 70: Healthcare Infrastructure, Singapore, Nurses (per 1,000 Population), 2008-2013 194
Figure 71: Healthcare Infrastructure, Singapore, Midwives (per 1,000 Population), 2008-2013 195
Figure 72: Healthcare Infrastructure, Singapore, Dentists (per 1,000 Population), 2008-2013 196
Figure 73: Healthcare Infrastructure, Singapore, Pharmacists (per 1,000 Population), 2008-2013 197
Figure 74: Healthcare Infrastructure, Singapore, Healthcare Expenditure (% of GDP), 2008-2013 199
Figure 75: Healthcare Infrastructure, Singapore, Public-Private Share (%), 2008-2013 200
Figure 76: Healthcare Infrastructure, Singapore, Share of Expenditure of Major Components of Healthcare Spending (%), 2014 202
Figure 77: Healthcare Infrastructure, Singapore, RandD Expenditure ($m), 2008-2013 204
Figure 78: Healthcare Market, Singapore, Opportunities and Challenges, 2014 211

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Germany Healthcare IT Market Outlook to 2022 - Clinical IT Systems, Medical Imaging Information Systems, Remote Patient Monitoring, Neonatal Monitors, Fetal Monitors, Blood Pressure Monitors, Micro-Electromechanical Sensors, Multiparameter Patient Monitor

Germany Healthcare IT Market Outlook to 2022 - Clinical IT Systems, Medical Imaging Information Systems, Remote Patient Monitoring, Neonatal Monitors, Fetal Monitors, Blood Pressure Monitors, Micro-Electromechanical Sensors, Multiparameter Patient Monitor

  • $ 5995
  • Industry report
  • November 2016
  • by Global Data

Germany Healthcare IT Market Outlook to 2022 - Clinical IT Systems, Medical Imaging Information Systems, Remote Patient Monitoring, Neonatal Monitors, Fetal Monitors, Blood Pressure Monitors, Micro-El ...

Australia Healthcare IT Market Outlook to 2022 - Clinical IT Systems, Medical Imaging Information Systems, Remote Patient Monitoring, Neonatal Monitors, Fetal Monitors, Blood Pressure Monitors, Micro-Electromechanical Sensors, Multiparameter Patient Monit

Australia Healthcare IT Market Outlook to 2022 - Clinical IT Systems, Medical Imaging Information Systems, Remote Patient Monitoring, Neonatal Monitors, Fetal Monitors, Blood Pressure Monitors, Micro-Electromechanical Sensors, Multiparameter Patient Monit

  • $ 5995
  • Industry report
  • November 2016
  • by Global Data

Australia Healthcare IT Market Outlook to 2022 - Clinical IT Systems, Medical Imaging Information Systems, Remote Patient Monitoring, Neonatal Monitors, Fetal Monitors, Blood Pressure Monitors, Micro- ...

India Healthcare IT Market Outlook to 2022 - Clinical IT Systems, Medical Imaging Information Systems, Remote Patient Monitoring, Neonatal Monitors, Fetal Monitors, Blood Pressure Monitors, Micro-Electromechanical Sensors, Multiparameter Patient Monitorin

India Healthcare IT Market Outlook to 2022 - Clinical IT Systems, Medical Imaging Information Systems, Remote Patient Monitoring, Neonatal Monitors, Fetal Monitors, Blood Pressure Monitors, Micro-Electromechanical Sensors, Multiparameter Patient Monitorin

  • $ 5995
  • Industry report
  • November 2016
  • by Global Data

India Healthcare IT Market Outlook to 2022 - Clinical IT Systems, Medical Imaging Information Systems, Remote Patient Monitoring, Neonatal Monitors, Fetal Monitors, Blood Pressure Monitors, Micro-Electromechanical ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.